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Themyokine irisin is supposed to be cleaved from a transmembrane precursor, FNDC5 (fibronectin type III
domain containing 5), and to mediate beneficial effects of exercise on human metabolism. However,
evidence for irisin circulating in blood is largely based on commercial ELISA kits which are based on
polyclonal antibodies (pAbs) not previously tested for cross-reacting serumproteins.We have analyzed four
commercial pAbs by Western blotting, which revealed prominent cross-reactivity with non-specific
proteins in human and animal sera. Using recombinant glycosylated and non-glycosylated irisin as positive
controls, we found no immune-reactive bands of the expected size in any biological samples. A FNDC5
signature was identified at ,20 kDa by mass spectrometry in human serum but was not detected by the
commercial pAbs tested. Our results call into question all previous data obtained with commercial ELISA
kits for irisin, and provide evidence against a physiological role for irisin in humans and other species.
I
n 2012, Bostro¨m et al.1 described irisin as a cleaved and secreted part of the transmembrane protein FNDC5
(fibronectin type III domain containing 5). They proposed irisin as an exercise-induced myokine triggering
‘‘browning’’ of white adipose tissue. These findings sparked a debate mainly turning on two issues: (I) the
relevance of irisin in humans, (II) the specificity of commercially available enzyme-linked immunosorbent assays
(ELISA), and more specifically the polyclonal antibodies on which they were based.
First, following the initial study1, it was realized that the start codon of the human FNDC5 gene ismutated from
the normal ATG to ATA. There are examples of proteins being expressed from unusual start codons2, however,
Raschke et al.3 found that FNDC5 transcripts derived from the AUA start codon were translated to protein with
extremely low efficiency as compared to the normal AUG start codon. All other animal species have an ATG as
start codon at this position. This suggests that the human species has an effective gene knockout of FNDC5 and,
consequently of irisin. Furthermore, Timmons et al.4 expressed doubts about the response of FNDC5mRNA in
human muscle to exercise, based on their previous and larger data sets, which showed no such response.
Nevertheless, a number of research groups around the world have examined the effects of exercise on irisin
levels in human serum. These studies, mostly using commercial ELISA kits that are questioned here, have given
contradictory results. Huh et al.5 observed a significant increase in serum irisin in response to acute exercise after 1
week of moderate training whereas no effect of acute exercise was found after 8 weeks of training intervention.
Short term effects of exercise on irisin levels were also reported by some authors5–9. In contrast, no systematic
effects of exercise on circulating irisin were found in several other studies10–17.
Second, the FNDC5 antibody used in the initial study1 was raised against the C-terminus of the protein (amino
acids [aa] 149–178), which is not part of the cleaved irisin peptide (aa 32–143; GenPept accession number
NP_715637). Thus, as initially noted by Erickson18, the 20 kDa band detected in western blots in that study
should not be irisin, but is probably a non-specific cross-reacting protein. Further studies employed western blots
with different antibodies against this epitope and found immune-reactive bands in the range of 20–26 kDa in
serum or plasma of rats, mice and humans19–22. Again, all these antibodies were generated against the C-terminal
FNDC5 segment, which is not part of circulating irisin. An antibody raised against partial irisin (aa 42–112),
which should detect irisin, stained a band at 25 kDa as well as bands of highermolecular weight inwestern blots of
the secretome of cultured rat muscle cells and adipocytes21. In previous studies, we used an antibody against full-
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length irisin (aa 32–143) and observed an immune-reactive band at
,13 kDa, the theoretical size of non-glycosylated irisin, in murine
serum but not in bovine plasma23,24.
The therapeutic potential of irisin to fight obesity and diabetes has
aroused extensive interest. Several commercial sources have mar-
keted kits for ELISA, EIA, and RIA to detect and quantify irisin in
different biological fluids, under different exercise interventions and/
or in different diseases (reviewed by Sanchis-Gomar et al.25, Elsen
et al.26). A striking feature of these investigations was the vast vari-
ation of reported irisin levels, differing by orders of magnitude even
in healthy subjects. This was the case for results obtained with tests
from different manufacturers but also with the same test from a
single supplier used in different laboratories. More than 80 studies
have been published with irisin levels ranging between 0.01 andmore
than 2,000 ng/mL in human serumor plasma. These commercial kits
were usually tested for the ability to detect bacterially expressed irisin
(recombinant protein produced in the bacterial cytoplasm, and
therefore not glycosylated), and a wide range of sensitivity was
reported. For example, a polyclonal antibody used in an ELISA kit
(designated here pAb-A) was reported by the supplier to have a
detection range of 0.38–205 ng/mL, and a linear range of 4–41 ng/
mL.We believe this is an acceptable validation of the sensitivity of the
ELISA kit for assaying purified recombinant irisin, in the absence of
other proteins.
However, in addition to recognizing the specific antigen, polyclo-
nal antibodies often cross-react with non-specific proteins. When an
ELISA kit, based on a polyclonal antibody against irisin, is used to
assay a complex protein sample such as plasma or serum, the signal
will include that from any irisin but also that from cross-reacting
proteins. Some of these may be present at high levels and can dom-
inate the signal. To control for this, it is necessary to validate the
antibody by western blot in the target tissue or fluid. Western blots
were shown in the original study1, but these showed multiple strong
cross-reacting proteins and were based on an inappropriate polyclo-
nal antibody18. Only a few of the subsequent studies have presented
full-size western blots that reveal cross-reacting proteins in plasma or
serum21,23,24,27. Many studies using only ELISA have apparently
ignored the possibility of cross-reacting proteins contributing to
the signal.
In our present study, we examined the specificity and sensitivity of
currently available irisin antibodies by comparative western blot
analysis. For standards we produced recombinant non-glycosylated
irisin (rNG-irisin), which runs on SDS-PAGE as a sharp band at
13 kDa, and recombinant, glycosylated irisin (rG-irisin), expressed
in mammalian HEK293 cells and running as a smeared band at 18–
25 kDa, with a peak at about 20 kDa. By diluting rNG-irisin into
plasma and running western blots we achieved two calibrations:
determination of the sensitivity of the assay for irisin, and detection
of cross-reacting proteins of various molecular weights. We then
extended the assay to survey a range of animal species for the pres-
ence of irisin in serum or plasma. In addition, we analyzed samples
from a previously published training intervention study13 with an
additional ELISA and western blots to compare irisin levels obtained
with different methods. Mass spectrometry was used to search for
FNDC5 or irisin signatures in human serum at different sizes after
SDS-PAGE. Finally, RNA sequencing was employed to gain insight
about the abundance of different transcripts of FNDC5 in human
muscle.
Results
Detection of rNG-irisin with pAb-A. Dilution series of rNG-irisin
into either phosphate buffered saline (PBS) or bovine plasma were
analyzed with anti-irisin pAb-A, raised against full length NG-irisin
(Fig. 1a). Bovine plasma was used for the initial test because our
previous study had shown no detectable circulating irisin24. Two
murine sera with unknown irisin levels, human serum samples
with irisin levels previously measured with a corresponding ELISA
kit (based on pAb-A), and a murine muscle sample were analyzed on
the same blot. The antibody reacted with a single band at ,13 kDa
in PBS and bovine plasma containing the higher concentrations of
added rNG-irisin (Fig. 1a). This band could be completely quenched
by preincubation of the primary antibody with 5-fold the amount of
rNG-irisin (Fig. 1b). Densitometric analysis of the irisin dilution in
bovine plasma revealed linearity in the range from 4 to 0.125 ng
irisin/lane (lanes 10–15 in Fig. 1a; R2 5 0.9947, Fig. 1c). Recovery
Figure 1 | Western blot of dilution series of rNG-irisin, using pAb-A.
(a) rNG-irisin was diluted into PBS (lanes 1–8; absolute amounts 20, 4, 2,
1, 0.5, 0.25, 0.125, 0.0625 ng irisin/lane) or diluted in bovine plasma (lanes
9–16; identical amounts). Two samples of mouse serum (lanes 17, 18) and
samples of human serum (lanes 19–24) are included. Mouse muscle
protein extract is in lane 25. (b) pAb-A was blocked with 5-fold amount
rNG-irisin prior to staining the blot. Images were taken after 2 (a) and
4 (b)min exposure to adjust for different background chemiluminescence,
and were equally enhanced in contrast. (c) Band volumes of recombinant
NG-irisin (lanes 9–15 in (a)) were densitometrically analyzed and
plotted against irisin amount (ng) in bovine serum. The highest (20 ng)
and lowest (0.0625 ng) concentrations were omitted from this analysis.
www.nature.com/scientificreports
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rates for the spiked irisin ranged from 75% to 96% in the lanes used
for determination of linearity. Because the sample contained 1 mL of
plasma we were able to detect irisin at a concentration of 125 ng/mL
with this western blot.
The western blot showed several cross-reacting proteins staining
much more intensely than even the higher concentrations of added
NG-irisin. The band at ,45 kDa is approximately the size for IgG.
However, cross-reaction of IgG with the secondary detection system
can be excluded because the TrueBlotH system used here is designed
to avoid reaction with denatured IgG, and control blots omitting the
primary antibody showed no unspecific staining. The band at
,30 kDa is too large to be irisin. The smear from 50–70 kDa and
the higher molecular weight bands include albumin and unknown
proteins. However, it is clear that these cross-reacting proteins would
dominate the signal if this pAb-A is used to assay bovine plasma or
human serum.
Notably, irisin was not detected by pAb-A in human serum
although levels between 324 and 864 ng/mL were previously
reported using the corresponding ELISA kit13. This is equivalent to
absolute amounts between 0.324 and 0.864 ng/lane on the blot
(Fig. 1a), clearly in the linear range of detection by our western blot.
A weak band slightly smaller than rNG-irisin was visible in murine
serum, but as discussed below is apparently not irisin.
The experiment was repeated with antibodies pAb-B, C, and D
(Supplementary Fig. 1). All antibodies proved capable of detecting
rNG-irisin added to PBS or bovine plasma in a similar linear range.
However, none of them stained a band of the expected size for gly-
cosylated irisin in murine or human samples. A strong immune-
reactive band at,25 kDa was observed only with pAb-C in human
but not in murine samples which is the upper size limit for glycosy-
lated irisin. However, this band was not detected by any other irisin
antibody, thus it is probably a cross-reaction specific for pAb-C.
Analysis of serum samples with pAb-E (raised against aa 149–178
of FNDC5) revealed no specific band in serum but in murine muscle
extract it stained a sharp, single band with the size of full length
FNDC5 (,24 kDa; Fig. 2a). The strong doublet band at about
25 kDa stained uniquely by pAb-C (Fig. 2b) was tested for deglyco-
sylation. In contrast to rG-irisin, whose size was significantly reduced
by PNGase, the ,25 kDa doublet was unaffected (Fig. 2b,c). This
band was analyzed by mass spectrometry, described later.
Besides the variability in band patterns observed between the
tested antibodies, a high lot-to-lot variability was observed for anti-
bodies pAb-A and C (Supplementary Fig. 2). Different lots of anti-
bodies pAb-B and D were not compared.
Western blot analysis of irisin in serumand plasma ofmammalian
species. Sera were analyzed from 3 horses undergoing extreme
physical exercise (160 km endurance race) and from 1 horse with
established metabolic syndrome. For comparison, samples from cattle,
domestic pig, wild boar, donkey, goat, rabbit and mouse were included
(Fig. 3). Human samples with irisin levels of 76 ng/mL and 864 ng/
mL, previously measured with ELISA (pAb-A), were from 1 healthy
and 1 pre-diabetic individual prior to or 2 hours after a single bout
of acute exercise13. All samples were analyzed by western blot with
antibodies pAb-A and pAb-C (Fig. 3a,b). Recombinant NG- and rG-
irisin were used as positive controls. No antibody detected proteins at
the size of the positive controls, indicating that neither non-glyco-
sylated nor glycosylated irisin circulated in the serum/plasma of any
species. However, immune-reactive bands were observed at,16 kDa
in a human sample and at,25 kDa in both human and goat samples
with pAb-C. These bands were consequently further analyzed by
HPLC/mass spectrometry.
Separate analysis of 11 samples from 6 horses with pAb-C showed
a similar band pattern to that in lanes 3–6 (Fig. 3b). Band volumes
were not related to physical activity or disease and were not corre-
lated to results obtained with pAb-B on the same samples (Supple-
mentary Fig. 3).
Comparison of ELISA data with semi-quantitative western blot
analyses. A total of 156 serum samples from 26 individuals from
a previously published exercise study13 were re-analyzed with an
additional irisin ELISA based on pAb-C and by semi-quantitative
western blot analysis with antibody pAb-C. Irisin levels were pre-
viously measured with ELISA based on pAb-A and the data were
used for correlation analyses with the results of the present study.
Western blot analyses revealed 3 prominent bands at ,16 kDa
(larger than rNG-irisin), ,25 kDa, and ,30 kDa in all samples
(Fig. 4a). The 16 kDa band was not observed in previous tests with
pAb-A (Fig. 1a). Regions of interest were selected and individual band
volumes were measured densitometrically (Fig. 4b). There was no
significant correlation between normalized volumes of any of the 3
bands or their combined volumes and irisin concentrations measured
with the corresponding ELISA kit (pAb-C; r 5 20.109, p 5 0.46;
Fig. 4c). Furthermore, irisin levels measured with the 2 different
ELISA kits differed by a factor 18 on average (overall means 2,961
ng/mL vs. 164.5 ng/mL) and were not correlated at all (r 5 0.034,
p 5 0.67; Fig. 4d). In contrast, the volume of a non-specific band
observed at ,50 kDa with pAb-A (Fig. 4e) was significantly corre-
lated to irisin levels measured with the corresponding ELISA (pAb-A)
in an arbitrarily selected subset of samples (n 5 24, r 5 0.730, p ,
0.001; Fig. 4f). Thus, using the ELISA based on pAb-C (Supple-
mentary Fig. 4) we were unable to repeat the previous finding of an
acute effect of exercise on irisin levels in serum, which used an ELISA
based on pAb-A13.
Immuno-precipitation and protein identification by mass spectro-
metry. The immuno-reactive bands at,25 kDa stained by pAb-C in
human (Supplementary Fig. 1b, Fig. 3b) and goat serum (Fig. 3b) were
purified by immuno-precipitation with pAb-C cross-linked to mag-
netic beads (Fig. 5a,b). An additional band at ,16 kDa observed
earlier in human serum (Fig. 3b) was also included in subsequent
mass spectrometric analysis. No peptide corresponding to FNDC5
or its irisin-part was identified in any of the precipitated samples in
Figure 2 | Western blots for detection of FNDC5 and irisin. (a) pAb-E,
which reacts with a C-terminal peptide (outside the irisin domain) was
used to detect full-length FNDC5. This pAb-E detected no band in human
serum samples (lanes 1–3), but mouse muscle extract showed a sharp
band at ,25 kDa.(lane 4). (b, c) pAb-C was used to stain rNG-irisin
(lane 1), G-irisin (lane 2) and human serum samples (lanes 3, 4) before
(b) and after (c) deglycosylation with PNGase. All images were taken after
10 min of exposure without contrast enhancement.
www.nature.com/scientificreports
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2 repeats of the experiment. Instead, apolipoprotein A1 was identified
as a predominant protein in both human and goat bands. The human
band of lower molecular weight included mainly Ig kappa chains and
hemoglobin subunits.
We then spiked rNG- and rG-irisin into human sera and analyzed
bands matched to the size of the recombinant control peptides by
HPLC/mass spectrometry (Fig. 5c,d). Samples of human serum with-
out addition of rNG- or rG-irisin were applied to the same gels. Gel
pieces at the positions corresponding to the size of the controls were
cut out and analyzed by HPLC/mass spectrometry even though no
staining with Coomassie Blue was observed. Unique peptide signa-
tures for FNDC5 or irisin (MLRFIQEVNTTTR or FIQEVNTTTR,
Fig. 6a) were detected in samples with added 100 ng or 500 ng rNG-
irisin in bands at,13 kDa. The doublet band visible in human serum
without addition (lane 4 in Fig. 5c) contained no FNDC5 or irisin.
Specific signatures for FNDC5 or irisin were found at ,20 kDa in
human serum with 100 ng or 500 ng rG-irisin added. The respective
gel piece from a serum sample without added rG-irisin (lane 4 in
Fig. 5d) revealed no visible band but contained a single peptide sig-
nature unique for FNDC5 or irisin (FIQEVNTTTR) among 13 other
proteins. Besides this, the results from mass spectrometry supported
the assumption of massive non-specific reaction of proteins with
irisin antibody pAb-C.
Expression of FNDC5mRNA in human skeletal muscle. Re-analysis
of samples ofm. vastus lateralis from control and pre-diabetic subjects
in a training intervention study by RNA-sequencing confirmed a small
but statistically significant increase of total FNDC5 mRNA levels after
12 weeks of exercise compared to baseline levels (fold change 5 1.185,
p , 0.001). Effects of the health status were not observed in accor-
dance to the previous analysis13.
The current NCBI RefSeq model of the human FNDC5 gene pre-
dicts 3 transcripts (T1: NM_001171941.2, T2: NM_153756.2, T3:
NM_001171940.1). Transcript 1 is proposed to be produced by
alternative splicing from an upstream exon 1a, whereas the two other
transcripts share exon 1b (Fig. 6a). Transcript 1 would produce a
truncated FNDC5 protein from an in-frame AUG codon in exon 3,
and the proposed irisin peptide would miss the first 44 amino acids.
However, the Kozak sequence around this AUG is very weak and
there are 3 other upstream out-of-frame AUG codons that would
make translation of this truncated protein unlikely. Thus, analysis of
154 muscle biopsies in the training intervention study13 revealed no
expression of exon 1a specific for this transcript. In contrast, tran-
scripts 2 and 3were expressed at high levels as indicated by the data of
their shared exon 1b (Fig. 6b). A dissection of the expression to
specific transcripts 2 or 3 is not possible due to the structure of the
locus (Fig. 6a). All investigated 26 individuals possessed the non-
canonical AUA start codon.
Discussion
Almost 3 years after the discovery of irisin1 the debate over its poten-
tial role in human metabolism has not been settled. Only recently,
Elsen et al.28 noted that the role of irisin in humans appears still
questionable despite the numerous studies. Spiegelman & Wrann29
commented in reply that there are more than 45 articles reporting
human irisin levels measured with a variety of immunoassays with
independently derived antibodies and thus they considered the exist-
ence of human irisin in blood a closed issue. However, not one of
those studies has addressed the possibility that the immunoassays
might be reporting cross-reacting proteins in serum or plasma, and
not irisin itself.
Our present study examined 4 antibodies of which 3 were used in
corresponding ELISAs. More than 80 studies have been published
based on these assays. We showed that all antibodies had prominent
cross-reactions with non-irisin proteins in serum or plasma of dif-
ferent species. For one antibody we found a strong correlation
between the volume of a prominently stained ,50 kDa band in
human serum, which is clearly not irisin, and irisin levels measured
with the corresponding ELISA. In contrast, no correlation was found
between irisin levels measured with 2 different ELISA kits. Earlier
comparisons of different ELISA kits reported only weak correlations
and considerable differences in absolute values12,30. Our data indicate
that all previously published assays based on commercial ELISAs,
including the more than 45 articles mentioned by Spiegelman &
Wrann29, were reporting unknown cross-reacting proteins.
Figure 3 | Western blot of serum or plasma samples of different species with irisin antibodies pAb-A (a) and pAb-C (b). Images were taken after 10 min
(a) and 20 min (b) exposure and equally enhanced in contrast. Boxes indicate bands of rNG-irisin (rNGI), rG-irisin (rGI), and synthetic (SI) irisin.
Samples in lanes 20–25 differ between (a) and (b).
www.nature.com/scientificreports
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Importantly, our Western blots failed to detect irisin or glycosy-
lated irisin in plasma or serum of human and several animal species,
even after extreme exercise in the case of horses. A 13 kDa band in
mouse serum, identified previously as potential irisin23, was stained
by pAb-A, but not by -B, -C or -D. This strongly suggests that it is also
a cross-reacting protein specific to pAb-A. The detection limit of the
most sensitive western blots was about 100 ng/mL being a potential
limitation of this study. However, this corresponds to approximately
10 nM which is below the concentration of recombinant FNDC5 or
irisin (20 nM) used in cell culture assays1,31. Because hormones are
typically present in circulation at pM to nM concentrations, it cannot
be ruled out that circulating irisin at less than 10 nM could have
activity in vivo.
Our data on FNDC5 expression in skeletal muscle demonstrate
that the human gene is exclusively translated from transcripts with a
mutant start codon. Considering the translation efficiency of such
transcripts – 1% compared to transcripts with a canonical start
codon3 – very low amounts of FNDC5 could be expected in skeletal
muscle. Hence, it is unlikely that irisin can be cleaved and secreted
into circulation at amountsmeasuredwith ELISAs previously. This is
further supported by the observation that acute exercise did not cause
a significant up-regulation of FNDC5 and that themRNA abundance
increased only slightly after 12 weeks of training intervention.
In contrast to most studies, which have neglected the possibility of
cross-reaction, a recent study22 employed western blots of human
serum as the first step. These blots showed several strong cross-
Figure 4 | Semi-quantitative analysis of western blots with pAb-C and comparison with ELISA data (based on pAb-A and pAb-C). (a) Western
blot (pAb-C) of serum samples of 4 individuals (lanes 1–4) at 6 time points (lanes a–f). RNG-irisin was included as positive control (lane 5). The image
was taken after 10 min exposure. (b) Quantification of chemiluminescence of targeted bands (crosses) in marked lanes. Note that contrast enhancement
in the region of measurement is only for visualization and does not influence the results. This measurement was done in all 156 samples from 26
individuals of a previous study13. (c) Plot of normalized, combined band volumes against irisin levels measured with ELISA based on pAb-C. (d) Plot of
irisin levels measured with ELISA based on pAb-A against ELISA based on pAb-C. (e) Quantification of a band (crosses) at 50 kDa detected by western
blot of human serum samples with pAB-A. Samples were arbitrarily chosen from the previous study13. (f) Volume of the non-specific 50 kDa band was
plotted against irisin concentration measured with ELISA based on pAb-A.
www.nature.com/scientificreports
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reacting bands of higher molecular weight, but the study focused on
bands of 32 and 24 kDa, interpreting them as glycosylated and degly-
cosylated irisin. As shown in our present report the molecular
weights of purified rG- and rNG-irisin are actually 20 and 13 kDa,
so the bands identified in that study22 are too large. Furthermore,
they used the same antibody as Bostro¨m et al.1, designated pAb-E
here, which was raised against a C-terminal sequence that is not
included in irisin. Finally, they analyzed the 32 and 24 kDa bands
by mass spectrometry and reported a single tryptic peptide corres-
ponding to the irisin sequence. We did not find any FNDC5 or irisin
signatures in our immune-precipitated bands identified by western
blots of human serum. However, we were able to detect irisin spiked
into human serum at the predicted size for glycosylated and non-
glycosylated irisin.
Mass spectrometry analysis of the ,20 kDa zone cut from SDS-
PAGE of human serum detected a peptide corresponding to FNDC5
or irisin. This is the same peptide identified by Lee et al22, although
they found it in,32 and,24 kDa bands stained with a pAb against
C-terminal FNDC5. Consequently, our result is the first mass spec-
trometry identification of an irisin peptide at the correct size, and
might be considered as supporting the existence of irisin in human
serum.However, none of the tested irisin antibodies stained a band at
this size in serum. This underlines that glycosylated irisin has not
been detected by western blot before and that none of the ELISA kits
used in previous studies have measured irisin levels in serum or
plasma of any species.
The birth of the new, promising myokine irisin1 has been compli-
cated from the beginning by multiple contradictions and obscurities
in the interpretation of western blot data18. Numerous subsequent
studies relied on ELISAs with commercial antibodies that were not
sufficiently validated in biological fluids. This resulted in highly con-
tradictory data concerning the existence of irisin and its role in
humans and other species. Our study targeted the basic question
behind the controversy – the physical existence of the proposed
cleavage product of FNDC5 in circulation. The key to this was to
use western blots to visualize and avoid the false signal from cross-
reacting proteins of the polyclonal antibodies, and to use recombin-
ant, non-glycosylated and glycosylated irisin as positive controls. In
addition to calling into question all previous studies using commer-
cial ELISAs, we found no evidence for circulating irisin in human or
several animal species when examined by western blot with 4 differ-
ent antibodies and a sensitive detection system. Although we report
the first peptide signature size-matched to rG-irisin by HPLC/mass
spectrometry in human serum, the apparently low concentration –
below the detection limit of the tested antibodies – makes a physio-
logical role for irisin very unlikely. Atherton & Philips32 raised the
question whether irisin is a ‘‘Greek goddess or a Greek myth’’. Our
results provide experimental evidence for irisin being a myth.
Methods
Ethical approval. The human exercise study named MyoGlu adhered to the
Declaration of Helsinki and was approved by the National Regional Committee for
Medical and Health Research Ethics North, Tromsø, Oslo, Norway. The study was
registered with the US National Library of Medicine Clinical Trials registry
(NCT01803568). Written informed consent was obtained from all participants prior
to any study-related procedure. Equine blood samples were taken in accordance with
the local animal ethics committee (Etat de Vaud, Service Ve´te´rinaire, Switzerland).
Figure 5 | Identification of proteins by mass spectrometry. (a) Western blot of human and caprine serum before (lanes 1, 4) and after (lanes 2, 3)
immuno-precipitation with pAb-C. Bands of interest are within white boxes. (b) Coomassie-stained gel with the same samples. After immuno-
precipitation, target bands (black boxes) were cut out of the gel and analyzed. (c) Coomassie-stained gel with 500 ng rNG-irisin in PBS (lane 1), 500 ng
and 100 ng rNG-irisin added to human serum (lanes 2 and 3) and human serum without addition (lane 4). Serum samples were albumin-depleted prior
to electrophoresis. Gel pieces within black boxes were cut out and analyzed. (d) Addition of rG-irisin instead of rNG-irisin. Samples and procedure are as
in (c). M: molecular weight marker.
www.nature.com/scientificreports
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Strength and endurance training intervention. Healthy, sedentary men (40–65
years) were recruited in 2 groups; controls with normal weight (23.56 2.0 kg/m2) and
normal fasting and 2 h serum oral glucose tolerance test (OGTT) levels (n 5 13) or
overweight (29.0 6 2.4 kg/m2) with abnormal glucose metabolism (pre-diabetes
group, n 5 13). Abnormal glucose metabolism was defined as fasting glucose $
5.6 mmol/L and/or impaired glucose tolerance (2 hours serum OGTT$ 7.8 mmol/
L). The participants underwent 2 endurance bicycle sessions (60 min) and 2 whole-
body strength-training sessions (60 min) per week for 12 weeks. A 45 min bicycle
session at 70% ofVO2maxwas performed before and after the 12week training period
as an acute work challenge13.
Blood and tissue sampling. Blood and muscle samples were taken before, directly
after, and 2 h after the 70% of VO2max bicycle test, before as well as after 12 weeks of
training. Blood samples were taken by standard antecubital venous puncture. Biopsies
fromm. vastus lateralis were immediately rinsed in phosphate buffered saline (PBS),
dissected free of blood, before they were transferred to RNA-later (Qiagen, Limburg,
Netherlands; overnight at 4uC) and finally transferred to 280uC. Serumwas stored at
280uC until analysis.
Animal serum and plasma samples. Samples for species comparison were obtained
from commercial suppliers (donkey, goat, rabbit), from previous studies in swine and
wild boar33, and from our own investigations in cattle24 and mice23. These samples
were not further characterized and represented the respective species only.
Serum of a horse that underwent a moderate physical exercise program (45 min
with intervals of walking, trotting and 3 times 1500 m at a speed of 8.5, 8.4, and
10.3 m/s) was sampled in the Swiss National Stud in Avenches (Switzerland)
immediately and 30 min post exercise. Further samples were taken from 5 horses
immediately or 60 min after participation in a 160 km endurance race (Ramboulliet,
Figure 6 | FNDC5 transcripts and deduced peptides. (a) Transcript structure of human FNDC5 (T1: NM_001171941.2, T2: NM_153756.2, T3:
NM_001171940.1) and deduced peptide structure (P1–P3). Numbers refer to nucleotides (T1-3) or amino acids (P1–3). Black bars represent exons. Exon
numbers are given in circles. Start and stop codons are indicated above the bars. The irisin peptide is marked by a bold box. The open box marks the
truncated irisin peptide in P1 theoretically resulting from transcript T1. The size of irisin and FNDC5 protein variants is given. The peptide signature
identified by mass spectrometry is marked in red. SP: signal peptide. (b) Example for detection of FNDC5 transcripts by RNA-sequencing of skeletal
muscle biopsies. Exon 1a is specific for transcript T1 whereas exon 1b is part of transcripts T2 and T3. The panels represent results for one individual
before (A1–A3) and after 12 weeks of training intervention (B1–B3). A1 and B1 were measured before, A2 and B2 immediately after, and A3 and B3
2 hours after acute exercise13.
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France). One horse with confirmed metabolic syndrome was sampled at the Swiss
Institute of Equine Medicine (ISME), Vetsuisse Faculty, University of Berne.
Expression and purification of recombinant, non-glycosylated and glycosylated
irisin. For convenient his-tag removal, the bacterial irisin expression construct34 was
modified by inserting the 3C protease cleavage sequence (LEVLFQGP) in the Nde I
site. This modification dramatically reduced protein solubility when it was expressed
in E. coli BL21 (DE3) at 37uC, so the his-3C-irisin construct was expressed in E. coli
C41 (DE3)35 at room temperature. Expressed proteins were purified with a cobalt
column (TALON; Clontech, Mountain View, USA) using standard protocols.
Purified proteins eluted with imidazole from the column were dialyzed against
phosphate buffered saline (PBS, pH 7.2) in the presence of his-tagged 3C protease at
4uC. After dialysis, samples were run through the cobalt column again to remove
uncleaved his-tagged irisin, cleaved his-tagged portions and his-tagged 3C protease.
Non his-tagged irisin was recovered in the flow through fraction from the cobalt
column. The amino acid sequence of rNG-irisin (no his-tag) is gphmSPSAP-
VNVTVRHLKANSAVVSWDVLEDEVVIGFAISQQKKDVRMLRFIQEVNTTT-
RSCALWDLEEDTEYIVHVQAISIQGQSPASEPVLFKTPREAEKMASKNKDE-
VTMKE (the sequence in lowercase is derived from the vector). Recombinant G-
irisin was produced in mammalian cells34. The irisin expression construct (irisin/
pHLSec2) was transfected into HEK293 cells and the conditioned medium was
collected after 6-7 days of transfection. Secreted protein was purified with the cobalt
column and the C-terminal his-tag was not removed. The amino acid sequence of rG-
irisin is egsADSPSAPVNVTVRHLKANSAVVSWDVLEDEVVIGFAISQQKKDV-
RMLRFIQEVNTTTRSCALWDLEEDTEYIVHVQAISIQGQSPASEPVLFKTPR-
EAEKMASKNKDEVTMKEefhhhhhhh. Glycosylation was verified by a molecular
weight shift in SDS-PAGE after PNGase F (NEB, Ipswich, USA) treatment. The
concentrations of purified proteins were estimated from the absorbance at 280 nm
using the extinction coefficients of the proteins determined by the Protean computer
program (DNAstar, Madison, USA).
In one experiment synthetic irisin (Catalog # 067-16; Phoenix Europe, Karlsruhe,
Germany) was used as an additional control.
Antibodies. The following antibodies were used in this study: pAb-A, rabbit
polyclonal antibody (pAb) to irisin (Phoenix Europe, Karlsruhe, Germany); pAb-B,
rabbit pAb to irisin (Cayman Chemicals, Ann Arbor, USA); pAb-C, rabbit pAb to
irisin (AdipoGen, Liestal, Switzerland); pAb-D, rabbit pAb to irisin (Phoenix
Europe); and pAb-E, rabbit pAb to FNDC5 (C-terminal; BioCat, Heidelberg,
Germany). Antibodies pAb-A and C were raised against full length rNG-irisin and
pAb-B and D against the full-length synthetic irisin peptide. Antibody pAb-E was
generated against the C-terminus of FNDC5, which is not part of the irisin peptide.
Details on the antibodies are given in Table 1.
Western immunoblotting. For dilution series, rNG-irisin was diluted into either PBS
or bovine plasma. Irisin stock solution (1 mg/mL in PBS) was first diluted 15100 in
bovine plasma resulting in minimal dilution of plasma proteins. This recombinant
NG-irisin solution was further diluted in bovine plasma to final concentrations of 10,
2, 1, 0.5, 0.25, 0.125, 0.0625, and 0.03125 ng/mL. Twomicroliters of each sample were
then mixed 152 with loading buffer (23 Laemmli sample buffer with 10% b-
mercaptoethanol), denatured at 95uC for 5 min and separated on Criterion TGX 12%
polyacrylamide gels (BioRad). Absolute amounts of rNG-irisin analyzed per lane
were consequently between 20 ng and 0.0625 ng. Each 1 mL of native murine and
human serum samples and 20 mg murine muscle protein extract were treated as
described above and electrophoresed on the same gel.
For species comparison, 1 mL of serum or plasma from the following species was
used: horse, cattle (bull, cow, calf), pig (domestic and wild), donkey, goat, rabbit,
mouse, and human. Samples were analyzed under the same conditions as described
above. Recombinant NG-irisin (2 mL from 1 ng/mL stock solution) and rG-irisin
(1 mL from 10 ng/mL stock solution) were used as positive controls.
Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane
(Trans-Blot Turbo transfer pack, Bio-Rad, Munich, Germany) using a semi-dry
blotter (Trans-Blot, Bio-Rad). Equal loading of the gels and proper transfer of the
proteins to the membranes were verified by Coomassie Blue staining according to
standard procedures. Membranes were blocked for 1 h in either 13 Roti-Block
(Roth), for detection of irisin (pAb-A, B, C and D), or in 5% non-fat dry milk in Tris-
buffered saline (TBS) for detection of FNDC5 (pAb-E). Membranes were incubated
with primary antibodies (pAb-A: diluted 153,000, pAb-B: 15500, pAb-C: 152,000,
and pAb-E 151,000) overnight at 4uC.
After washing, membranes were incubated with horseradish peroxidase-conju-
gated secondary antibody (rabbit IgG TrueBlot, 1525,000; 18–8,816, eBioscience,
Frankfurt, Germany). Antibody label was detected with chemiluminescence substrate
(Super Signal West Femto, Thermo Fisher Scientific, Bonn, Germany) and a
Chemocam HR-16 imager (INTAS, Go¨ttingen, Germany). LabImage 1D software
(Kapelan Bio-Imaging, Leipzig, Germany) was used to quantify the volumes of spe-
cific bands.
Analysis of serum irisin. Concentrations of irisin were measured in duplicates in
human serum using enzyme-linked immuno-sorbent assays (ELISA [based on pAb-
C]; Table 1) according to the manufacturer’s protocol. Optical density was
determined using a microplate reader (Termo Scientific Multiscan EX, Vantaa,
Finland) set to 450 nm. Data from a previous measurement of irisin in plasma
samples of the same individuals13 with a different ELISA (based on pAb-A; Table 1)
were used for comparison. Letters assigned to the ELISAs correspond to the letters
designated to the antibodies.
Immuno-precipitation and SDS-PAGE of serum samples with added irisin.
MagnaBind magnetic beads (Pierce, Thermo Fisher Scientific, Bonn, Germany), pre-
coated with anti-rabbit IgG antibody, were incubated with anti-irisin antibody
(Adipogen) for 60 min under permanent agitation (Dynabeads MX Mixer, Life
Technologies, Darmstadt, Germany). Separation steps were performed using
InviMag (STRATEC, Berlin, Germany) magnetic separator. Binding of antibodies to
the beads was made permanently according to standard protocols by using cross-
linking buffer (25 mMDMP) at room temperature for 45 min. To stop the reaction,
blocking buffer (0.1 M Ethanolamine in PBS, pH 8.2) was used. Unbound antibody
was eluted from the beads with elution buffer (1 M glycine-HCL, pH 3). Serum
(500 ml) was denatured for 5 min at 95uC and added to the antibody coated beads.
Incubation was performed overnight at 4uC under permanent agitation. After several
washes, proteins were eluted from beads with elution buffer (1 M glycine-HCL,
pH 3). To optimize the protocol for subsequentmass spectrometry, the elution buffer
was changed (8 M urea, 20 mM Tris pH 7.5, 100 mM NaCl) according to standard
protocols (abcam, Cambridge, U.K.) in a repeated trial.
Eluted proteins were separated on a 15% polyacrylamide gel and stained with
QuickCoomassie (Serva, Heidelberg, Germany) according to manufacturer’s
instructions. Bands of interest were cut out of the gel and submitted to analysis by
mass spectrometry. Furthermore, human serum samples were albumin-depletedwith
AurumAffi-Gel Bluemini columns (Bio-Rad) as described elsewhere24. One hundred
or 500 ng of either rNG- or rG-irisin were then added to the samples. The samples
(20 mg total protein) were separated by SDS-PAGE (15%) and stained with
QuickCoomassie (Serva). Serum samples without addition of rNG-/rG-irisin were
also analyzed. Recombinant NG-/rG-irisn (500 ng) diluted in PBS were used for size
comparison. Regions of interest were cut out of the gel and analyzed by mass
spectrometry.
Protein identification bymass spectrometry.The Coomassie stained gel bands were
in-gel digested using trypsin. The generated peptides were purified using m-C18
ZipTips (Millipore, Oslo, Norway), dried in a SpeedVac, dissolved in 10 mL 1% formic
acid, 2.5% acetonitrile in water. Half of the volume was injected into a nano-UHPLC
system (Ultimate 3000 RSLC, Dionex, Sunnyvale, CA, USA) coupled to an ESI-ion
trap/Orbitrap (LTQ Orbitrap XL, Thermo Scientific, Bremen, Germany) mass
Table 1 | Polyclonal irisin antibodies used in this and related ELISA kits
Designation
(this study)
Manufacturer/
Vendor (Cat. #) Antigen (epitope)1
Manufacturer
(ELISA #) Range of ELISA2 Remarks
pAb-A Aviscera/Phoenix
(G-067-52)
recombinant irisin
(aa 33–142)
Phoenix (EK-067-52) 0.3–205
ng/mL
antibody discontinued; ELISA
replaced by EK-067-29
pAb-B Cayman (14625) synthetic irisin
(aa 33–142)
- - no ELISA available
pAb-C Adipogen
(A-25B-0027)
recombinant irisin
(aa 33–142)
Adipogen
(AG-45A-0046EK)
1.0–5,000
ng/mL
antibody is epitope
affinity purified
pAb-D Phoenix
(G-067-16)
synthetic irisin
(aa 33–142)
Phoenix (EK-067-16) 0.1–1,000
ng/mL
ELISA not used in this study
pAb-E BioVision/BioCat
(AP8746b-AB)
C-terminus of FNDC5
(aa 149–178)
- - no ELISA available antibody
is epitope affinity purified
1refers to GenPept accession number NP_715637.2.
2data of manufacturer/vendor.
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spectrometer. For peptide separation, an Acclaim PepMap 100 column (50 cm 3
75 mm) packed with 100 A˚ C18 3 mm particles (Dionex; Nerliens Meszansky, Oslo,
Norway) was used with a flow rate of 300 nL/min and a solvent gradient of 3% B to
35% B for 45 min. Solvent A was 0.1% formic acid and solvent B was 0.1% formic
acid/90% acetonitrile. Survey full scan MS spectra (from m/z 300 to 2000) were
acquired in theOrbitrapwith the resolution R5 60,000 atm/z 400 after accumulation
to a target of 1,000,000 charges in the LTQ. The method allowed sequential isolation
of up to the 7most intense ions for fragmentation on the linear ion trap using collision
induced dissociation (CID) at a target value of 10,000 charges. Target ions already
selected for MS/MS were dynamically excluded for 60 sec. Data were acquired using
Xcalibur v2.5.5 (Thermo Scientific) and raw files were processed to generate peak list
in Mascot generic format (*.mgf) using ProteoWizard release version 3.0.33136.
Database searches were performed using Mascot in-house version 2.4. to search the
SwissProt database assuming the digestion enzyme trypsin, at maximum one missed
cleavage, fragment ionmass tolerance of 0.60 Da, parent ion tolerance of 10 ppm and
oxidation of methionines, and acetylation of the protein N-terminus as variable
modifications. Scaffold (version Scaffold_4.3.4, Proteome Software, Portland, USA)
was used to validate MS/MS based peptide and protein identifications. Peptide
identifications were accepted if they could be established at greater than 95%
probability by the Scaffold Local FDR algorithm. Protein identifications were
accepted when they could be established at greater than 99% probability and
contained at least 2 identified peptides.
High throughput mRNA sequencing and differential expression analysis. Skeletal
muscle biopsies sampled before the start of acute exercise at baseline and after 12
weeks of training were deep-sequenced in 6 batches using the Illumina HiSeq 2000
system (Illumina, San Diego, USA) with multiplexing at the Norwegian Sequencing
Centre, University of Oslo. Samples in different groups and time points were
multiplexed between batches to avoid batch effects. Illumina HiSeq RTA (real-time
analysis) v1.17.21.3 (Illumina) was used for real-time analysis during the sequencing.
Reads passing Illumina’s recommended parameters were demultiplexed using
CASAVA v1.8.2 (Illumina). For prealignment quality checks we used the software
FastQC v0.10.1. (Babraham Bioinformatics, Cambridge, UK). To avoid low quality
data negatively influencing downstream analysis, reads were trimmed on the 39-end
and only the first 51 bp from the 59-end of each read were kept for further analysis.
The mean library size was,44 million unstranded 51 bp single-ended reads with no
difference between groups or time points. Base composition in bases 1–12 showed
patterns typical for RNA-seq and bases 13-51 were evenly distributed. All base
positions were of high quality (Phred score .30). Alignment of sequenced cDNA
reads to the RefSeqGene database as transcriptome reference and quantitative
analysis of the transcripts was done as described by Li et al. (2014)37.
Statistical analysis. ELISA and western blot data were analyzed with ANOVA using
PROCMIXED (SAS Institute, Cary, USA) with the following factors included in the
model: fixed factor group and repeated factor treatment (with unstructured
covariance structure) and corresponding interaction, plate and blot were included as
random effect, respectively. Differences betweenmeans were considered significant if
p , 0.05. Pearson correlation coefficients were calculated among quantitative data
from ELISAs and western blots.
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